Ingenza
- Company typePrivate
- Founded2003
- HeadquartersEdinburgh, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
Ingenza firmographics
Firmographics- Name
- Ingenza
- Legal name
- Ingenza Limited
- Website
- https://ingenza.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Ingenza industry classification
Industry- Product category
- Biopharmaceutical Contract Research Development and Manufacturing (CRDMO)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)
- akta.pro secondary industries
- Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where Ingenza is headquartered
LocationHeadquarters
- HQ city
- Edinburgh
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Ingenza business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Contract Research and Manufacturing Services: As a CRDMO, Ingenza provides fee-for-service preclinical and process development services through to first-in-human manufacturing. Revenue is generated through project-based contracts with pharmaceutical and biotech companies requiring protein production, strain development, and bioprocess optimization.
- Technology Licensing: Ingenza licenses its proprietary technologies (such as inABLE®) to third parties. Syngenta has exercised commercial licensing options for enabling technologies developed by Ingenza.
- Technology License Income (Bioethanol): Innovate UK grant funding supports commercialization of production technology targeting the bioethanol yeast market, with potential to generate substantial technology license income.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based custom engagements |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Ingenza product offering
Product offeringCore offering
Ingenza is a full-service protein Contract Research, Development and Manufacturing Organization (CRDMO) providing strain/cell line engineering, fermentation, process development, analytical development, and cGMP-ready material manufacturing for biologics, small molecule pharmaceuticals, and sustainable biotech applications. The company combines proprietary AI/ML tools (codABLE™) and its inGenius® CMC platform with multidisciplinary human expertise to deliver protein therapeutics and biocatalytic processes from discovery through first-in-human trials. It also licenses enabling technologies such as inABLE® to third parties and operates a multi-host production platform spanning E. coli, Bacillus subtilis, Pichia pastoris, and CHO cells.
Product overview
Ingenza operates as a protein Contract Research, Development and Manufacturing Organization (CRDMO) with a platform-plus-services architecture. The core inGenius® technology platform is enhanced by specialized AI/ML capabilities (codABLE™ for gene design optimization) and proprietary tools (inABLE® for DNA recombination). The service portfolio spans three main divisions—Biologics, Small Molecule, and Sustainable Biotech—each offering strain/cell line development, process development, analytical development, and material manufacturing. Specialized offerings include GenXpress Bacillus (an orthogonal protein production system), the inGenius® CMC platform for drug development, and diagnostic products like ester-impregnated pH strips. The company serves Human and Animal Health and Sustainable Technologies markets, combining AI tools with human expertise through a dual-engineering approach.
Differentiator
Problem solved
Functional benefit
Brands
- inGenius®: Proprietary chemistry manufacturing and controls (CMC) platform that accelerates and de-risks progression of novel drug candidates from strain/cell line development through to first-in-human trials.
- codABLE™
- inABLE®
- GenXpress Bacillus
Products and services
- Biologics CRDMO Services Full-service biologics development including strain/cell line engineering, process development, analytical development, and cGMP material manufacturing, supporting drug discovery through preclinical evaluation and first-in-human studies for pharmaceutical and biotech clients.
- Small Molecule CRDMO Services Engineering of efficient microbial production of natural products and biocatalytic regio- and enantio-selective synthesis of small molecule pharmaceuticals, chiral synthons, and advanced intermediates for pharmaceutical and chemical clients.
- Sustainable Biotech CRDMO Services Deployment of sustainable bioprocesses for chemicals, enzymes, and custom solutions using diverse host organisms to achieve industrial performance, cost competitiveness, and Net Zero objectives for chemical, biofuel, and industrial biotech clients.
- codABLE™ AI/ML Gene Design Platform AI/ML-driven gene design platform that uses machine learning to predict and tune recombinant protein expression by analyzing codon usage patterns, achieving predictive gene design for maximized production yields across E. coli, Bacillus subtilis, Pichia pastoris, and CHO hosts.
- GenXpress Bacillus Protein Production System Orthogonal protein production system using engineered Bacillus host, providing performance comparable to E. coli expression systems and serving as a highly productive alternative for endotoxin-free biologics manufacturing.
- inGenius® CMC Platform Chemistry Manufacturing and Controls platform that accelerates and de-risks progression of novel drug candidates from biosynthetic route and production host selection through optimized genetic design, strain/cell line development, bioprocessing, and production of materials for preclinical and first-in-human clinical trials.
- inABLE® Enabling Technology Licensing Licensed proprietary suite of gene expression and DNA recombination tools used for developing enabling technologies, including capabilities for cyclic peptide production, DNA assembly, and synthetic biology applications, licensed to third parties such as Syngenta for crop protection.
Quantifiable outcome
- 100% success rate producing customer targets
- +5 more outcomes
Companies that use Ingenza
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Ingenza technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability3 records
Feature5 records
Ingenza partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Ab BiotechnologycoreStrategic relationship with Ab Biotechnology, a MHRA-licensed GMP facilities provider, to support development and GMP manufacturing of innovative biotechnology products. Located in close proximity, enabling integrated service delivery.
- HydRegencorePartnership with Oxford-based biotech company HydRegen to develop a more sustainable method for manufacturing amine-based chemicals, eliminating heavy metal catalysts. Ingenza helped improve expression levels of a new candidate biocatalyst (Bio2Amine), increasing process efficiency and resource use. Resulted in much greater improvement in enzyme expression levels in a short period.
- CellugyminorCollaboration with Denmark-based Cellugy to accelerate development of its platform for producing biofabricated cellulose. Focus on implementing techniques to identify key factors influencing cellulose production pathway and improving yield and productivity.
- OpviaminorStrategic partnership with Opvia as QMS (Quality Management Systems) provider. Opvia's eQMS solution centralizes and manages Ingenza's quality management practices for process development and biomanufacturing operations.
- Phibro EthanolcoreLong-standing partnership (since 2017) with Phibro Ethanol, a division of Phibro Animal Health Corporation, to engineer novel yeast strains that increase bioethanol yield under challenging and conventional conditions. Key strategic customer and partner.
- Lucite Internationalcore10-year collaboration with Lucite International (world's largest MMA producer, part of Mitsubishi Chemical) to develop biological manufacturing routes for methyl-methacrylate (MMA) with lower carbon footprints. Partners with universities of St Andrews, Strathclyde, Aberdeen, and Nottingham on related projects.
- University of OxfordcoreCollaboration with University of Oxford on pan-sarbecovirus 'mosaic-8' vaccine program alongside Caltech, CPI, and CEPI. Also involved in subunit-vaccine development work with Professor Emeritus Alain Townsend. Oxford partnership dates back to COVID-19 vaccine development.
- California Institute of Technology (Caltech)corePartnership with Caltech on next-generation coronavirus vaccine (mosaic-8) development. Caltech and Oxford developed initial nanoparticle vaccine; Ingenza provides scalable manufacturing platform.
- Centre for Process Innovation (CPI)coreCollaboration alongside Caltech and Oxford on COVID-19 vaccine technology development and manufacturing.
- AmprologixcorePartnership with University of Plymouth spin-out Amprologix for development and scale-up of epidermicin NI01 antibiotic. Ingenza holds a stake in Amprologix and provides biologics manufacturing platform. Project received £1.2M Innovate UK funding.
- Mitsubishi Chemical Corporationcore'Unleashing Putida' project to develop Pseudomonas putida as host for biobased methyl methacrylate production. Collaboration with Mitsubishi Chemical Corporation (Japan) and Mitsubishi Chemical Methacrylates (UK).
- Imperial College LondoncoreClinical validation study for ester-impregnated pH strips in 10 NHS hospitals. Imperial College London conducted modelling showing potential to avoid 132 unnecessary X-rays per 1,000 patients, saving £4,034 per 1,000 patients.
- SyngentacoreSyngenta exercised commercial licensing option for enabling technology using inABLE® suite for development of innovative crop protection products.
Scale indicators10 records
Recent moves9 records
Expansion highlights5 records
Ingenza competitors and assessment
Company assessmentDirect peers
- Biovian: European CDMO specializing in microbial (E. coli, Pichia) expression for biologics and ATMPs. Closely comparable mid-sized peer with similar multi-host protein production capabilities as Ingenza.
- Codexis: Engineering biology company using AI/ML-driven enzyme engineering for pharmaceutical and sustainable chemicals applications. Comparable to Ingenza's biocatalysis and small-molecule development expertise, with similar focus on protein optimization.
- AGC Biologics: CDMO specializing in microbial and mammalian biologics manufacturing, including E. coli, yeast (Pichia), and CHO expression systems. Closely comparable to Ingenza in offering multi-host process development and GMP manufacturing for clinical-stage biologics.
- Cobra Biologics (Charles River): Specialist CDMO offering microbial (E. coli) and mammalian expression, viral vector, and cell therapy services from UK facilities. Comparable mid-sized peer for Ingenza's biologics and gene therapy process development work.
- Cytovance Biologics: US-based CDMO offering microbial and mammalian biologics process development and cGMP manufacturing. Directly comparable peer for Ingenza's mid-scale clinical biologics manufacturing capabilities.
Broad incumbents
- Lonza: Global leader in biologics CDMO services offering mammalian and microbial expression, process development, and GMP manufacturing across all clinical phases. Directly competes with Ingenza in protein-based biologics, but operates at vastly larger scale with multi-site global capacity.
- WuXi Biologics: One of the largest biologics CDMOs globally, providing end-to-end discovery, development, and manufacturing services. Overlaps with Ingenza's biologics development and manufacturing offerings but at much larger scale, particularly in mammalian cell culture.
- Samsung Biologics: Large-scale biologics CDMO offering mammalian cell line development, process development, and cGMP manufacturing. Competes with Ingenza for mammalian-based biologics programs but operates from mega-scale Korean facilities.
- Eurofins CDMO: Global CDMO and contract testing services spanning biologics, small molecules, and analytical services. Competes with Ingenza in contract process development and analytical services across multiple therapeutic modalities.
Emerging players
- Ginkgo Bioworks: Synthetic biology platform combining engineering biology with AI/ML for strain engineering and biomanufacturing. Comparable to Ingenza's codABLE™ and inABLE® technology approaches for cell programming and protein production, though broader in scope.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Ingenza social profiles
Digital presenceIngenza compliance and trust
Trust signalCompliance1 record
Ingenza financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ingenza leadership team
Management profileNumber of profiles
Profiles17 records
Ingenza funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ingenza M&A and investment
M&A and investmentM&A
Investments5 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ingenza
What does Ingenza do?
Ingenza is a full-service protein Contract Research, Development and Manufacturing Organization (CRDMO) providing strain/cell line engineering, fermentation, process development, analytical development, and cGMP-ready material manufacturing for biologics, small molecule pharmaceuticals, and sustainable biotech applications. The company combines proprietary AI/ML tools (codABLE™) and its inGenius® CMC platform with multidisciplinary human expertise to deliver protein therapeutics and biocatalytic processes from discovery through first-in-human trials. It also licenses enabling technologies such as inABLE® to third parties and operates a multi-host production platform spanning E. coli, Bacillus subtilis, Pichia pastoris, and CHO cells.
Is Ingenza a public or private company?
Ingenza is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Ingenza founded?
Ingenza was founded in 2003. It employs 11 to 50 people.
Where is Ingenza based?
Ingenza is headquartered in Edinburgh, United Kingdom, in the Europe region.
How does Ingenza make money?
Three revenue lines are on record. Contract Research and Manufacturing Services are the primary driver. The others are technology Licensing and technology License Income (Bioethanol).
Who are Ingenza's main competitors?
Direct peers on record are Biovian, Codexis, AGC Biologics, Cobra Biologics (Charles River) and Cytovance Biologics. Broad incumbents are Lonza, WuXi Biologics, Samsung Biologics and Eurofins CDMO. Ginkgo Bioworks is listed as an emerging player.
Does Ingenza have an API?
No public API is recorded for Ingenza.
What industry is Ingenza in?
Ingenza's product category is Biopharmaceutical Contract Research Development and Manufacturing (CRDMO). Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling). Its NAICS code is 541714 and its SIC code is 8731.